05.12.25 -- 8 Actions To Redefine Sponsor–CDMO Relationships

Delve into why investing in a comprehensive feasibility program for GOI testing is not just beneficial, but absolutely essential for cell and gene therapy companies.

In a recent webinar, Novartis Contract Manufacturing experts explored innovations in viral vector manufacturing and addressed production challenges and quality control strategies.

See why collaboration and innovation are key to overcoming challenges and bringing life-changing cell and gene therapies to those in need.

Explore how TARGATT gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

To ensure the success of gene therapy, learn why it is crucial to partner with a CRO that can navigate the challenges of viral vector development and testing.

Learn how plasmid engineering can boost AAV productivity and packaging efficiency across serotypes and client-specific Genes of Interest in upstream production.

Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.

Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.